Objective: Our goal was to validate this simple injury/regeneration system and use it to study the biology of newly forming adult cardiac myocytes. again the results have been highly variable. [11][12][13] A recent study by Ellison et al 10 used a single dose of subcutaneous isoproterenol (ISO) to induce what was described as a takotsubolike cardiomyopathy. This study showed that a single injection of ISO causes death of ≈10% of the cardiac myocytes in the mouse heart, and over the next month, there is complete cardiac regeneration. The newly formed cardiac myocytes in this study were exclusively derived from cKit + CSCs. Our laboratories have studied myocyte regeneration in multiple small and large animal cardiac injury models, including continuous ISO infusion via osmotic minipumps, 5 myocardial infarction (MI), 14 MI in the presence of cardiotoxic agents, 15 and MI with exogenous implantation of CSCs. 14 All of these studies have shown low rates (<1%) of new myocyte formation. The recent study by Ellison et al 10 describes a simple system that should be easily reproduced and would be a useful system to study the properties of newly forming cardiac myocytes in the adult heart. The goal of the present study was to validate the data suggesting that a single ISO injection in mice kills ≈10% of the cardiac myocytes, and that over the next month, these are replaced by new myocytes derived from endogenous CSCs.
M
any forms of cardiovascular disease can lead to death of cardiac myocytes. Effective repair requires the generation of new cardiac muscle cells; however, the adult myocyte has lost all or most of its ability to reenter the cell cycle and divide. 1 Therefore, stem cells with the capacity to differentiate into new cardiac myocytes could be useful for cardiac regeneration. Endogenous cKit + cardiac stem cells (CSCs) were first described over a decade ago. 2 There has been great debate over their ability to form new myocytes in the normal adult heart or to regenerate new cardiomyocytes after injury. Some studies suggest that these cells can robustly form new myocytes in the aging heart 3 or in the adult heart after injury, [2] [3] [4] [5] whereas others find very small numbers of new myocytes during aging or after injury. 6 A minority of studies suggest that these cells cannot differentiate into new myocytes. 7 
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The rate of new myocyte formation (myocyte turnover) in the normal adult mammalian heart is also not well established, with recent studies reporting annual rates of myocyte turnover at 1% 8 or 4% to 10% 9 in humans and as low as 0.003% 5 or as high as 8% to 10% 10 in rodent studies using a variety of cell fate-mapping strategies.
The ability of the adult mammalian heart to regenerate in response to multiple forms of injury has been studied, and again the results have been highly variable. [11] [12] [13] A recent study by Ellison et al 10 used a single dose of subcutaneous isoproterenol (ISO) to induce what was described as a takotsubolike cardiomyopathy. This study showed that a single injection of ISO causes death of ≈10% of the cardiac myocytes in the mouse heart, and over the next month, there is complete cardiac regeneration. The newly formed cardiac myocytes in this study were exclusively derived from cKit + CSCs. Our laboratories have studied myocyte regeneration in multiple small and large animal cardiac injury models, including continuous ISO infusion via osmotic minipumps, 5 myocardial infarction (MI), 14 MI in the presence of cardiotoxic agents, 15 and MI with exogenous implantation of CSCs. 14 All of these studies have shown low rates (<1%) of new myocyte formation. The recent study by Ellison et al 10 describes a simple system that should be easily reproduced and would be a useful system to study the properties of newly forming cardiac myocytes in the adult heart. The goal of the present study was to validate the data suggesting that a single ISO injection in mice kills ≈10% of the cardiac myocytes, and that over the next month, these are replaced by new myocytes derived from endogenous CSCs.
Our study establishes that a single ISO dose does indeed injure ≈10% of C57BL/6 mouse ventricular myocytes. However, the majority of these myocytes seem to recover normal function over the next few weeks. We also show that in spite of the ISO injury, there is a transient increase in ventricular function, rather than the decrease in cardiac function with widespread myocyte death described previously. 10 Additionally, we show that ISO injury did not increase the percentage of 5-ethynyl-2′-deoxyuridine (EdU + ) myocytes (<0.008%) or the percentage of myocytes derived from CSCs. We also show that inducing more severe cardiac injury with multiple injections of ISO did not elicit a robust regenerative response.
Methods
Please refer to the Materials and Methods section in the Online Data Supplement for a detailed description of experimental methods.
Experimental Animals
All animal procedures were approved by the Temple University School of Medicine Institutional Animal Care and Use Committee. For most mouse experiments, wild-type 10-to 12-week-old male C57BL/6 mice (n=173) were used (The Jackson Laboratory, Bar Harbor, ME). For fate mapping of endogenous c-kit + cardiac myocytes, constitutive and inducible Kit-Cre-IRES-GFPnls (n=9) or KitMerCreMer knock-in mice (n=5) were generated. 6 In short, the Kit locus was targeted in mice to express Cre recombinase and eGFP (enhanced green fluorescent protein) with a nuclear localization sequence. These mice were crossed with Cre-responsive Rosa26 mice (R-GFP) for lineage tracing.
ISO Dosing
Single-dose ISO was administered by subcutaneous injections. We used 200 mg/kg ISO and a higher dose of 300 mg/kg (as this was the highest tolerable nonlethal dose). For the chronic ISO experiments, 200 mg/kg ISO was injected twice daily for 6 consecutive days. For all experiments, a stock solution of 50 mg/mL ISO (Sigma-Aldrich No I6504, St Louis, MO) was prepared in sterile 0.9% saline.
Statistical Analysis
All data analyses were performed using SAS version 9.3. Data are shown as mean±SEM. A mixed-effects model approach was used for variables that were measured repeatedly. For variables that were measured only once, overall group comparisons were tested using the Kruskal-Wallis test or analysis of variance F test, when appropriate, whereas the pairwise group comparisons were performed using the exact Wilcoxon rank-sum test or unequal variance 2-sample t test.
Results

ISO Dosing
An ISO dose titration study was performed in mice to define a nonlethal ISO dose that injures the heart. Mice were injected with 5 (n=5), 200 (n=5), 300 (n=1), 400 (n=4), 500 (n=1), 600 (n=1), 700 (n=1), 800 (n=1), or 1000 mg/kg (n=5) ISO. Doses ≥400 mg/ kg caused death of every animal within a few hours. Therefore, vehicle (saline), 200 mg/kg (dose used by Ellison et al 10 ), and 300 mg/kg (highest nonlethal dose) were used for all experiments.
To document the lethal arrhythmias induced by high-dose ISO, continuous ECGs were recorded while animals were injected with 200, 300, 400, or 1000 mg/kg ISO. Injection of ISO induced many different types of arrhythmias. After injection of 400 and 1000 mg/kg, ECG tracings initially revealed a slight increase in heart rate (data not shown) followed by sinus arrest and heart block with a ventricular escape rhythm within a few minutes that ended either in lethal ventricular tachycardia or asystole (Online Figure I) .
ISO Transiently Increases Myocardial Contractility and Does Not Depress Diastolic Function
Mice were injected subcutaneously with vehicle (n=14), 200 mg/kg (n=15), or 300 mg/kg (n=14) ISO. All animals underwent baseline echocardiography (ECHO) before dosing and then at 1, 3, 7, 14, and 28 days after ISO/vehicle injection. Conventional ECHO revealed that 200 and 300 mg/kg ISO significantly increased left ventricular (LV) ejection fraction (EF) and fractional shortening (FS) after 1 day compared with baseline. Injection with 300 mg/kg ISO significantly increased EF (59.9±0.9% versus 69.3±2.5%; P<0.01) and FS (31.2±0.6% versus 38.8±2.1%; P<0.01) after 1 day compared with the vehicle-injected group (Figure 1A and 1B; Online Movies I-IV). Cardiac function returned to baseline levels at 1 week and was unchanged for the remainder of the study. End-systolic and enddiastolic volumes did not differ between groups at any time point ( Figure 1C and 1D ). Figure 1E shows representative M-mode images of all 3 treatment groups at baseline and 1 day post ISO injection. Heart rates during ECHO did not significantly differ between groups at any time point (Online Figure I) . Diastolic function was determined using ECHO coupled with pulsed Doppler and tissue Doppler imaging techniques. No differences in diastolic function (E, E/A, E′, EAT [acceleration time of the transmitral early diastolic peak flow velocity]; Online Figure II ) between groups at any time point were found.
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Subendocardial and Apical Myocardial Contractility Are Not Impaired After ISO Injury
To determine the effects of ISO on regional myocardial function, speckle tracking-based strain analyses on long-axis B-mode loops were performed. Because of myocardial fiber orientation at varying levels of the LV wall, longitudinal strain is most representative of myocardial shortening at the level of the endocardium. 16 Furthermore, the software allows analysis of regional wall segments. Consistent with the results from conventional ECHO, 300 mg/kg ISO significantly increased the magnitude of global longitudinal strain (Figure 2A ) compared with vehicle controls after 1 day (−22.26±0.98% versus Figure 3H ). The percentage of TUNEL + nonmyocytes was slightly increased after ISO, but this did not reach statistical significance ( Figure 3I ). Confirming these results, Western blot analysis revealed no increase in activated caspase-3 after ISO injection (Online Figure III) .
To further investigate ISO-induced myocyte injury, myocyte membrane permeability and necrosis were evaluated by measuring Evans Blue Dye (EBD) uptake 24 hours after ISO or vehicle injection. Figure 3D -3F shows representative images of EBD uptake and hematoxylin and eosin (H&E) staining of the matched histological sections from all 3 groups. Quantification of myocyte EBD uptake ( Figure 3G ) revealed a significant increase after 200 mg/kg (9.79±0.58%) and 300 mg/kg ISO (8.04±0.58%) compared with vehicle (0.04±0.02%; P<0.05). EBD uptake certainly defines ISOinduced membrane damage but does not necessarily document myocyte necrosis. 17, 18 We found areas of EBD + myocytes where the matching H&E-stained section revealed intact, nonnecrotic myocytes ( Figure 3E and 3F, lower small images). We also identified EBD + myocytes with histological features of necrosis ( Figure 3E and 3F, upper small images). These results suggest that ISO can alter myocyte membrane permeability without necessarily causing necrosis. EBD + myocytes were found throughout the ventricle and were not localized exclusively to the endocardium or the apical regions of the LV.
To further characterize injury induced by ISO, troponin I (Tn-I) levels were measured 24 hours after ISO injection in vehicle, 200 mg/kg, and 300 mg/kg ISO-injected mice and after MI induced by permanent occlusion of the left anterior descending artery, as a positive control ( Figure 3J ). Tn-I levels were significantly increased after 300 mg/kg ISO (8.2±1.9 ng/ mL; P<0.05) and after MI (58.1±7.1 ng/mL; P<0.01) compared with vehicle, whereas 200 mg/kg ISO caused only a slight increase in Tn-I, which did not reach statistical significance (0.4±0.2 ng/mL; P=NS). Injury with 300 mg/kg ISO caused a significantly higher increase in Tn-I levels compared with 200 mg/kg (P<0.05). Notably, compared with Tn-I levels after MI, 200 and 300 mg/kg ISO caused significantly smaller increases (P<0.01). In the vehicle group, the Tn-I levels were too low for quantification (<0.01 ng/mL). These results suggest that a single injection of either 200 or 300 mg/kg ISO caused transient changes in myocyte membrane permeability but that not all EBD + myocytes were necrotic.
Single ISO Injection Does Not Induce Cardiac Fibrosis or Change Heart Size in C57BL/6 Mice
Myocardial injury from MI, 15 pressure overload, or prolonged ISO infusion 5 elicits a fibrotic response that is associated with changes in myocardial diastolic compliance. If ISO caused significant myocardial necrosis, an increase in fibrotic area would be expected. Because we observed a significant increase in EBD uptake after ISO treatment, which is associated with myocyte injury, 19 we measured cardiac fibrosis. Masson's trichrome-stained tissue sections from hearts fixed at 4 weeks post ISO or vehicle injections were studied ( Figure 4A -4C shows representative images). Bioquantification analysis did not show significant differences in the percentage of fibrotic tissue between groups ( Figure 4G ). Furthermore, no changes in heart weight to body weight ratio (HW/BW) at 4 weeks post ISO were observed ( Figure 4H ), documenting the lack of organ hypertrophy.
Diseases that induce cardiac myocyte death are usually associated with hypertrophy of surviving myocytes. To explore this possibility, myocyte cross-sectional area was measured in Masson's trichrome-stained tissue sections ( Figure 4D -4F and 4I), and cell surface area was measured in myocytes isolated from vehicle and ISO-injected animals ( Figure 6B ). A trend toward an increase in myocyte size after ISO injury was observed, but this effect did not reach statistical significance. To further explore the idea that ISO injury induces reactive pathological hypertrophy, mRNA expression levels of the hypertrophic markers atrial natriuretic peptide, brain natriuretic peptide, and β-myosin heavy chain were measured at 1 and 4 weeks post ISO. In the 300 mg/kg ISO-treated animals compared with vehicle-treated controls ( Figure 4J ), significant increases in atrial natriuretic peptide and β-myosin heavy chain expression patterns were observed at 1 week. After 200 mg/ kg ISO injection, β-myosin heavy chain was also upregulated at 1 week. β-Myosin heavy chain expression in both groups 
ISO Does Not Increase EdU Incorporation in Myocyte Nuclei In Vivo
Our experiments show that ISO caused myocyte injury (EBD uptake in 10% of ventricular myocytes) but was not associated with an increase in fibrosis. These findings could be because of necrotic myocytes being replaced by CSC-derived new myocytes as suggested in the previous study 10 or because most of the damaged and EBD-labeled myocytes recover normal function. To assess whether ISO injury induces increased myocyte and nonmyocyte proliferation and DNA replication in vivo, an EdU pulse-chase labeling strategy was used. A similar approach with 5-bromo-2′-deoxyuridine (BrdU) has been used previously by our group to identify newly generated feline myocytes after cardiac injury caused by 10 days of continuous ISO infusion.
5 Figure 5A -5C displays representative confocal micrograph images of hearts treated with a single injection of vehicle or ISO (200 and 300 mg/kg) 1 week after injection and EdU labeling (via minipump). Quantitative histology ( Figure 5D ) revealed no differences in the percentage of EdU + myocytes between ISO-and vehicle-treated animals at 4 weeks (vehicle 0.08±0.01%, 200 mg/kg ISO 0.07±0.03%, 300 mg/kg ISO 0.09±0.03%; P=NS). ISO caused a significant dose-dependent increase in the percentage of EdU + nonmyocytes (vehicle 0.47±0.12%, 200 mg/kg ISO 2.5±0.15%, and Figure 5E ). After MI, a much larger number of EdU + nonmyocyte nuclei were observed in the injured border zone and infarct area, with fewer in the viable tissue of the remote zone (Online Figure IV) . These results suggest that ISO causes a dose-dependent injury that elicits a proportional postinjury inflammatory response.
To more conclusively document the percentage of EdU + myocytes, single cells were isolated from vehicle, 200 mg/ kg, or 300 mg/kg ISO-treated mice 4 weeks post ISO injection ( Figure 6 ). The percentage of EdU + cardiomyocytes was low and did not differ between groups (vehicle 0.007±0.003%, 200 mg/kg 0.006±0.003%, and 300 mg/kg 0.008±0.001; P=NS). Many of the EdU + myocytes were small and mononucleated ( Figure 6C ). Sixty-three percent of EdU + -isolated cardiomyocytes were mononucleated, 34% binucleated, and 3% multinucleated, whereas among all myocytes, 9.4% were mononucleated and 84.5% were binucleated ( Figure 6D ). These results suggest that there is a low rate of new myocyte formation in the adult C57BL/6 mouse, and this rate is not significantly increased after cardiac injury via a single injection of ISO.
ISO Does Not Increase CSC-Derived New Myocytes
To determine whether the new myocytes seen in these studies were derived from CSCs, transgenic mice that use the Kit locus for lineage tracing were used. 6 The constitutive Kit +/ Cre ×R-GFP mice (Kit +/Cre ×R-GFP) irreversibly mark any cell that previously or currently expresses cKit with green fluorescent protein (GFP). 6 These mice were injected with 200 mg/kg ISO, and after 4 weeks, myocytes were isolated or hearts were fixed for immunostaining. Figure 7A Cre ×R-GFP mice (0.0055±0.0004% versus 0.0053±0.0007%; P=NS). The low percentage of eGFP + myocytes is similar to that reported previously by van Berlo et al. 6 Tissue sections from hearts fixed at 4 weeks were stained for GFP (green) and α-sarcomeric actin (red; Figure 7E ). Sixteen sections from each heart were analyzed for GFP + myocytes. One to two GFP + myocytes were identified per entire heart section, which is consistent with findings from van Berlo et al. 6 The majority of GFP + cells in every section appeared to be endothelial cells. Furthermore, none of the GFP + myocytes were positive for EdU ( Figure 7F ). The EF in Kit 
Chronic ISO Causes Cardiac Injury Without Relevant New Cardiomyocyte Formation
We were concerned that our failure to see myocyte regeneration after a single ISO injection might have resulted from insufficient myocyte injury. Therefore, C57BL/6 mice were injected with 200 mg/kg ISO twice daily for 6 consecutive days. In contrast to a one-time ISO injection, multiple ISO injections caused a significant decrease in EF at 7 and 28 days post injection compared with vehicle-injected animals (28 days: ISO 48.0±2.9% versus vehicle 56.6±1.1%; P<0.05; Figure 8A ; Online Figure VI) . Furthermore, diastolic function, represented by an increased E/A ratio, was also significantly impaired at 7 and 28 days after ISO injection (28 days: ISO 3.8±0.5 versus vehicle 1.5±0.04; P<0.001; Figure 8B ; Online Figure VI) . However, the percentages of fibrotic area (data not shown), myocyte cross-sectional area (Online Figure VI) , and HW/BW ratio (Online Figure VI) were comparable to those of vehicle-injected mice, consistent with our findings after single ISO injection. The EdU pulse-chase labeling strategy revealed no differences in the percentage of EdU + myocyte nuclei between ISO-and vehicle-treated animals at 28 days after injections (ISO 0.12±0.03% versus vehicle 0.11±0.01%; P=NS; Figure 8C ). The percentage of EdU + nonmyocyte nuclei was significantly increased after multiple ISO injections (ISO 6.44±0.71% versus vehicle 0.52±0.06%; P<0.01; Figure 8D ). This rise significantly exceeded the percentage of EdU ×R-GFP mice were induced with tamoxifen for 2 weeks to activate the lineage tracing system. 6 In line with our findings in C57BL/6 mice, myocyte cross-sectional area (Online Figure VI) , HW/BW ratio (Online Figure VI) , and the percentage of EdU + myocyte nuclei (ISO 0.04±0.01% versus vehicle 0.08±0.02%; P=NS; Figure 8H ) were unaltered after ISO. Although there was a 4-fold increase in the percentage of EdU + nonmyocyte nuclei (ISO 15.6±1.64% versus vehicle 3.8±0.45%; P=NS; Figure 8I ), as well as an increase in the percentage of fibrotic area (ISO 2.7±0.13% versus vehicle 0.9±0.01%; P=NS; Figure 8G ; Online Figure VI ) in the ISO group compared with vehicle, both did not reach statistical significance, which is most likely explained by a small sample size. However, we did not observe any increase in eGFP + myocytes. Thus, chronic ISO exposure caused more robust cardiac injury and depressed systolic and diastolic function, but did not elicit ckit + -CSC-derived myocyte regeneration.
Discussion
The objective of this study was to validate published work 10 demonstrating that a single injection of ISO in mice induces myocyte necrosis localized to the ventricular endocardium and apex, with transient depression of cardiac pump function, followed by a regenerative response in which CSCs are activated to proliferate and differentiate into new cardiac myocytes that fully regenerate the myocardium. Our goal was to use this system to study the properties of newly forming adult cardiac myocytes. We conducted a dose titration study in C57BL/6 mice and demonstrated that ISO doses ≥400 mg/ kg were lethal. We then explored the effects of single injections of 200 mg/kg (the concentration used in the previous study 10 ), the highest nonlethal dose of 300 mg/kg, and chronic ISO administration for 6 days (to increase injury). We defined the effects of these ISO doses on cardiac systolic and diastolic function, myocyte injury, myocyte size, cardiac fibrosis, and new myocyte generation.
Single Injection of High-Dose ISO Causes Transient-Positive Inotropic Effects
ISO is a potent β-adrenergic agonist that increases systolic [Ca 2+ ] to enhance myocyte contractility. 20 Toxic levels of catecholamines or prolonged exposure can induce cardiac injury in part by inducing Ca 2+ overload-mediated myocyte necrosis. 21 The previous study 10 showed that a single injection of 200 mg/ kg ISO caused endocardial and apical myocyte death and reduced cardiac function. To validate these observations, we first performed comprehensive ECHO evaluation for 4 weeks after ISO injection, and we further performed speckle trackingbased strain imaging, a high-sensitivity method for phenotyping cardiac function. These techniques are known to detect small global and regional changes in contractility. 16, 22 Neither conventional nor strain analyses revealed any functional deterioration at any time point after ISO injection. In fact, we observed a transient enhancement of myocardial contractility (EF, FS, global longitudinal strain; Figures 1A, 1B, and 2A) 1 day after ISO injection compared with vehicle, consistent with the well-known positive inotropic action of ISO. Ellison et al 10 did not present ECHO data in mice, only hemodynamic measurements, where they demonstrated a significant decrease in LV-developed pressure and maximal rate of rise of pressure ( + dP/dt) 1 day post ISO injection that returned to normal baseline values after 28 days. The reasons why we were unable to confirm transient depression of global cardiac function is unclear.
The effects of single-dose ISO administration has been studied in other animal models. In an earlier 2007 study in rats, Ellison et al 23 reported that a single subcutaneous ISO (5 mg/kg) injection induced acute LV failure at 1 day with full recovery by 6 days. Sachdeva et al 24 described a takotsubo-like cardiomyopathy in rats after a single subcutaneous injection that used a 20-fold higher concentration than used by Ellison et al. 23 In mice, Shao et al 25 demonstrated LV systolic dysfunction 1 day after intraperitoneal injection of 400 mg/kg ISO. After 1 week, cardiac function was normalized, and no significant fibrosis was detected. 25 Our findings indicate that a single ISO dose (200 or 300 mg/kg) causes diffuse cardiac myocyte injury (EBD uptake) without reducing global cardiac function ( Figures 1A, 1B, and 2A) . Given the time course of the functional effects reported in these studies (either no change in global function or full recovery within a week), we conclude that a single injection of ISO injures the heart but does not cause widespread myocyte death. This is consistent with the findings that cardiac fibrosis was not observed, and heart function recovered quickly; if it was indeed reduced in these studies.
The previous study 10 showed that myocytes in the ventricular apex and subendocardium are killed after ISO injection and referred to their own study in rats. 23 However, they did not provide functional evidence of ISO-induced takotsubo-like cardiomyopathies in mice. Speckle tracking-based longitudinal strain analyses, which can define myocardial performance in individual cardiac segments and layers, 16 did not demonstrate regional apical or subendocardial impairments after ISO administration (Figure 2A-2D) . Therefore, from a functional point of view, a single ISO injection did not induce a takotsubo-like cardiomyopathy in C57BL/6 WT mice.
There have been reports of cardiac dysfunction after ISO injections in mice, but these studies have usually used multiple, serial, ISO injections. 26, 27 It seems clear that chronic ISO administration can induce myocardial injury with subsequent functional impairment, myocardial necrosis, fibrosis, and hypertrophy in rats and cats. 5, 24, [28] [29] [30] Studies in mice have shown that serial subcutaneous ISO administration induces hypertrophy, diastolic dysfunction, and increased myocardial fibrosis, but does not affect systolic function. 26, 27 Kudej et al demonstrated that chronic ISO administration via minipumps induced cardiac hypertrophy without cellular necrosis. 31 Hohimer et al highlighted that different routes of ISO administration have different hemodynamic sequelae and could potentially evoke different cardiac phenotypes in mice. 32 In our view, the variability in ISO effects on cardiac function reported in the literature likely results from different ISO dosing strategies.
ISO Causes Myocyte Injury Without Inducing Apoptosis or Widespread Necrosis
We did not observe a significant increase in the percentage of TUNEL + myocytes ( Figure 3H ) or nonmyocytes ( Figure 3I ) or an increase in activated caspase-3 (Online Figure III) after ISO exposure. These data suggest that apoptosis plays a minor role in ISO-induced myocardial injury, which is consistent with Ellison et al's 10 observations in mice and rats. We found that 200 and 300 mg/kg ISO caused ≈10% of the ventricular myocytes to take up EBD, documenting membrane permeability abnormalities. 19 EBD uptake is further associated with loss of membrane integrity and loss of mitochondrial membrane potential. 33, 34 Myocardial necrosis after ISO administration has been reported in several animal models, 5,10,23,24,35,36 but we did not find global functional defects or cardiac fibrosis. Therefore, we questioned if EBD + myocytes were indeed all destined for necrosis. H&E-stained slides of the matched EBD + sections showed some areas in which EBD + myocytes showed features of necrotic tissue ( Figure 3E and 3F, upper small images). However, many areas with EBD + myocytes showed no other histological features of necrosis (in the matched H&E sections; Figure 3E and 3F, lower small images). Others have shown that ISO can induce a transient alteration in sarcolemmal membrane permeability without necrosis. 17 A transient membrane instability could cause EBD uptake in some myocytes, with subsequent recovery after elimination of the stressor. Although Ellison et al 10 reported that 200 mg/kg ISO caused the same type of myocardial damage in mice and rats, they did not document how they measured myocardial ×R-GFP mouse at 4 weeks after 6 days of 2×/daily ISO (200 mg/kg) injections that was immunostained against laminin (white) and α-sarcomeric actinin (red). Endogenous eGFP fluorescence from the R-GFP reporter is shown in green. Nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI, blue). Individual fluorescent channels are shown alongside each image. Scale bars=100 μm (J) and 10 μm (K). NS=not significant (P<0.05). A-D and G-I, Data are shown as mean±SEM.
by guest on July 23, 2017 http://circres.ahajournals.org/ Downloaded from necrosis in mice. Interestingly, they reported that 200 mg/kg ISO caused necrosis in 10% of myocytes, which is similar to our findings with EBD uptake. In our study, Tn-I levels measured 1 day after ISO injection were significantly elevated after 300 mg/kg ISO, but not after 200 mg/kg ISO. In addition, we showed that ISO-injured animals had significantly lower levels of serum Tn-I levels compared with mouse hearts with MI (which clearly induces myocyte death, inflammation, and reactive fibrosis 15 ; Figure 3J ). In humans, Tn-I levels correlate with myocardial necrosis after radiofrequency ablation 37 and infarct volume after acute MI. 38 A close correlation between cardiac troponin T and histological infarct size has been observed in mice. 39 Interestingly, the increase in Tn-I after 300 mg/kg ISO was significantly higher compared with 200 mg/ kg ISO, which suggests increased injury. The percentage of EBD + myocytes was similar between 200 and 300 mg/kg ISO, suggesting that EBD uptake may identify both damaged (but able to recover) and necrotic cells. Collectively, our results suggest that a single sublethal ISO injection in C57BL/6 mice causes transient membrane damage in ≈10% of the myocytes, and some of these myocytes seem to undergo necrosis with a small, ISO dose-dependent increase in the infiltration of proliferative inflammatory cells, but no reactive fibrosis.
ISO Causes Dose-Dependent Injury Without Inducing Cardiac Regeneration
We used an EdU pulse-chase labeling strategy to identify newly forming myocytes and nonmyocytes at 4 weeks after ISO injury. Newly formed myocytes (from any source) that entered the cell cycle would be detected by EdU nuclear incorporation. The study by Ellison et al 10 showed that 8% to 10% of the ventricular myocytes were labeled with BrdU 6 and 28 days after 200 mg/kg ISO. We did not find any increase in EdU + myocytes at 4 weeks after injection with 200 or 300 mg/kg ISO ( Figure 5D ). We used EdU rather than BrdU in our study because, in our hands, detection of EdU is much more reliable. The smaller molecular size of the EdU reagents, higher diffusion rates, and more effective tissue penetration without denaturation allows for better structural preservation. 40 EdU could also label damaged DNA; thus, it is possible that we detected false-positive proliferating cells. Given the fact that only a few cardiomyocytes were EdU + (<0.10%) and the fact that most of these myocytes were small and mononucleated makes the idea that they represent damaged DNA rather than new DNA highly unlikely. Our findings suggest that there is a low rate of new myocyte formation in the adult mouse heart, and the rate of new myocyte formation is not increased significantly after ISO injury. The idea that the EdU + myocytes represent newly formed myocytes was strongly supported by our finding that these cells were largely mononucleated, whereas the majority of EdU − myocytes were binucleated ( Figure 6D ). We also explored whether ISO injury induces cardiac myocyte regeneration and whether new myocytes are derived from CSCs. We used a cKit lineage fate-mapping strategy in which Kit +/Cre ×R-GFP transgenic mice 6 were given a single 200 mg/ kg ISO injection. The results of these experiments were consistent with our EdU findings. 200 mg/kg ISO did not increase the percentage of eGFP + myocytes compared with control (untreated Kit +/Cre ×R-GFP). Interestingly, the percentage of EdU + -isolated myocytes observed after ISO injury or in controls was similar to the percentage of GFP + myocytes derived from CSCs (≈0.005%). The somewhat higher percentage of EdU + myocytes found in tissue sections could simply reflect differences in experimental approaches, such as difficulties with reliable identification of myocyte nuclei in tissue sections. Interestingly, none of the GFP + myocytes we identified after ISO injury had an EdU + nucleus ( Figure 7F ). These findings suggest that the new EdU + myocytes we observed may not have been derived from a cKit-expressing precursor cell.
Chronic ISO Causes Cardiac Injury Without Activating CSC-Mediated Regeneration
Multiple high-dose ISO injections were used to determine if a more pronounced cardiac injury could induce cardiomyocyte regeneration. In C57BL/6 mice, multiple high dose ISO injections caused significant impairments in systolic and diastolic function (Figure 8A MCM ×R-GFP mice. Furthermore, we cannot rule out strain-and sex-related differences in the response to ISO. Faulx et al reported that ISO causes a more pronounced cardiac injury in A/J than C57BL/6J mice, because of β-adrenergic receptor (β-AR) downregulation in C57BL/6J mice. 41 However, we do not think that sex and strain differences can account for the differences between Ellison's and our findings. caused in the present study induces a small regenerative response. The source of these new myocytes in the feline study could not be determined conclusively.
In summary, the current study shows that a single injection of 200 or 300 mg/kg ISO caused myocyte membrane permeability alterations sufficient to allow EBD uptake and Tn-I leak from ≈10% of the ventricular myocytes. These injured myocytes were observed diffusely throughout the heart and were not localized to the endocardium or apical regions of the heart. No reductions in global or regional myocardial performance were observed. Therefore, a single dose of 200 mg/kg ISO in mice does not produce a takotsubo-like cardiomyopathy in C57BL/6 mice. A small amount of myocyte necrosis was induced by ISO injury, and we found a small, ISO dose-dependent increase in the infiltration of proliferative inflammatory cells but no significant myocardial fibrosis that is normally associated with widespread necrotic injury. Multiple ISO injections caused a more pronounced cardiac injury with systolic and diastolic cardiac dysfunction. Although ISO induced a dose-dependent cardiac injury, we did not find any evidence for cardiac regeneration either after a single or after multiple injections of high-dose ISO, using 2 independent techniques and 2 ckit lineage tracing mouse models. Collectively, our results in mice do not support the idea that ISO injury elicits cardiomyocyte regeneration.
What Is Known?
• Endogenous cKit + cardiac stem cells have the ability to form new myocytes in the normal adult heart and to regenerate new cardiomyocytes after cardiac injury. However, the extent to which cardiac stem cells form new myocytes after cardiac injury is highly variable in different studies.
• High levels of circulating catecholamines can induce reversible cardiac stunning and myocyte death.
• A previous report showed that a single injection of isoproterenol (ISO; 200 mg/kg) kills 8% to 10% of the myocytes in the mouse heart, and over the 28 days, these lost myocytes are regenerated from cKit + cardiac stem cells.
What New Information Does This Article Contribute?
• A single ISO injection (200 or 300 mg/Kg) in C57BL/6 mice causes dose-dependent injury in 8% to 10% of the ventricular myocytes, but hearts recover without significant fibrosis or abnormal systolic and diastolic cardiac function.
• Single or multiple injections of ISO cause injury but do not induce an increase in the number of newly generated myocytes, as determined by ethynyl deoxyuridine labeling. Molkentin and Steven R. Houser isoproterenol injection and their hearts were perfusion-fixed and paraffin-embedded for histology. The body weight, heart weight and tibia length of all animals were recorded at sacrifice. The remaining animals (n=29) were dosed with saline. Animals (n=8) were sacrificed at 1 day post-ISO injection for troponin I measurements (n=4) and for Western blot analysis of activated caspase 3 (n=4). Animals (n=5) were sacrificed at 1 day post-ISO injection, and hearts were embedded in Optimal Cutting Temperature Compound and frozen in liquid nitrogen for myocyte necrosis analyses using Evan´s blue dye. Animals (n=4) were sacrificed at 1 week post-ISO injection, and hearts were frozen in liquid nitrogen for molecular biology studies. Animals (n=10) were sacrificed at 4 weeks post-ISO and hearts were either frozen in liquid nitrogen for molecular biology (n=4), enzymatically digested (n=4) for myocyte isolation, or perfusion-fixed and paraffin-embedded for histology (n=2). Animals (n=2) underwent continuous ECG monitoring.
The wild-type C57BL/6 mice (n=5) that received vehicle injections twice daily for 6 consecutive days underwent echocardiography at baseline, 7 and 28 days with tissue Doppler imaging (TDI) and strain analysis, and were sacrificed at 28 days post-injections. The hearts were perfusion-fixed and paraffinembedded for histology. The body weight, heart weight and tibia length of all animals were recorded at sacrifice.
The wild-type C57BL/6 mice (n=9) that received 200mg/kg ISO injections twice daily for 6 consecutive days underwent echocardiography at baseline, 7 and 28 days with tissue Doppler imaging (TDI) and strain analysis, and were sacrificed at 28 days post-injections. The hearts were perfusion-fixed and paraffin-embedded for histology. The body weight, heart weight and tibia length of all animals were recorded at sacrifice
During breeding of the c-kit-GFP transgenic animals, a total of 6 kit +/cre x R-GFP transgenic animals were generated along with 3 non-transgenic littermates. 7 of these animals received 200 mg/kg isoproterenol (4 kit +/cre x R-GFP transgenic and 3 non-transgenic) and underwent serial echocardiography. 2 transgenic mice served as a control and did not receive isoproterenol. All seven animals were sacrificed 4 weeks after injection. 2 of the transgenic kit +/cre x R-GFP transgenic mice were sacrificed at baseline and their hearts were perfusion digested for myocyte isolation to determine the percentage of GFP + myocytes present at baseline as previously described 1 . The hearts from the 3 non-transgenic animals and 2 transgenic animals were perfusion-fixed and paraffin-embedded for histology. The hearts of the remaining 2 transgenic females underwent perfusion digestion for myocyte isolation to determine the percentage of GFP + myocytes in each heart after isoproterenol injury. The body weight, heart weight and tibia length of all animals were recorded at sacrifice. Kit +/MCM x R-GFP (n=5) were injected either with 200mg/kg ISO (n=3) or saline (n=2) twice daily for 6 consecutive days and were sacrificed at 28 days (n=5) post-isoproterenol injections and their hearts were cut in half in longitudinal sections. Half were frozen in liquid nitrogen and the other half fixed in formalin and paraffin-embedded for histology. The body weight, heart weight and tibia length of all animals were recorded at sacrifice.
Isoproterenol Dosing
Single-dose isoproterenol (ISO) was administered by subcutaneous injection into the loose skin (Ellison et al., 2013 ) over the neck. The maximum dose used in their publication was 200 mg/kg for mouse studies. For our study, we used 200mg/kg ISO and a higher dose of 300 mg/kg (as this was the highest tolerable nonlethal dose). Doses greater than or equal to 400 mg/kg were lethal within 30 min of injection. For the chronic ISO experiments, C57BL/6 mice were either injected s.c. with 200mg/kg ISO (n=10) or vehicle (n=5) twice daily for 6 consecutive days. For all experiments, a stock solution of 50 mg/mL isoproterenol (Sigma-Aldrich #I6504; St. Louis, MO) was prepared in sterile 0.9% saline. This solution was aliquoted and stored at -20°C. Dilutions made from thawed stock solution were prepared within 30 minutes of injection in sterile 0.9% saline to achieve concentrations of 200 and 300 mg/kg. All diluted isoproterenol solutions were kept on ice and away from light until injection.
Animal Procedures
EdU Minipump Implantation, Subcutaneous Isoproterenol Injections, Echocardiography and Cardiectomy. Animals were weighed, assigned treatment groups (vehicle, 200 or 300 mg/kg isoproterenol) and sacrifice date (1 day, 1 week or 4 weeks post-isoproterenol injection) prior to the start of experimental procedures to avoid selection bias, and isoproterenol doses were calculated based on the recorded body weights at baseline. Osmotic minipumps (Alzet; Cupertino, CA) were loaded with solution containing 39.0625 mg/mL EdU (Life Technologies, Carlsbad, CA) dissolved in 50/50% mixture of DMSO/ddH2O. Pumps were prepared as
